Improvements Across Functional Systems Are Maintained Regardless of Early VS Late Confirmed Disability Improvement: CARE-MS 6-Year Follow-Up

Abstract

In CARE-MS studies (NCT00530348; NCT00548405), alemtuzumab showed significant improvement vs SC IFNB-1a in clinical/MRI outcomes over 2 years in patients with RRMS, including higher rates of confirmed disability improvement (CDI). Efficacy was maintained in a 4-year extension (NCT00930553). In CARE-MS II, 71% of patients with CDI achieved improvements in >1 EDSS functional system (FS) score; improvements were seen across all FS. The objective was to assess CDI occurring early/late after alemtuzumab initiation in pooled CARE-MS I and II patients over 6 years, including maintenance of effect and pattern of improvement across FS scores.